Experimental drug offered to lung cancer patients out of options
NCT ID NCT06841874
Summary
This program provides access to the experimental drug taletrectinib for adults with advanced ROS1-positive lung cancer who have run out of approved treatment options and cannot join regular clinical trials. The drug aims to control cancer growth in patients who have already tried or cannot use other targeted therapies. This is not a cure but offers another treatment option when standard approaches have failed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.